Is BenevolentAI profitable in 2026?

No. BenevolentAI has never reported profitability; H1 2024 revenue was £2.8 million, down 46% year-on-year, against an operating loss of £32.3 million (as of September 2024). The company delisted from Euronext Amsterdam in March 2025 and has disclosed no new external capital since.

Has BenevolentAI had major layoffs?

Yes, severe cuts. Headcount fell from 363 employees in January 2023 to just 69 by December 2025, roughly an 80% reduction, via multiple rounds including a 50% cut in May 2023 and a 30% cut plus US office closure in April 2024.

Who owns BenevolentAI now that it's delisted?

BenevolentAI became private on 13 March 2025 after merging into Osaka Holdings S.a r.l., which then renamed itself BenevolentAI. Founder Ken Mulvany, who became Executive Chairman in October 2024, reportedly held about 23% of shares as of April 2024.

Could AI replace BenevolentAI's core business?

BenevolentAI's core service, knowledge-graph-based drug target identification, sits directly in the path of better-funded frontier AI labs. Isomorphic Labs, a Google DeepMind spinout, raised a $2.1 billion Series B in May 2026 and shipped its Drug Design Engine in February 2026, targeting the same layer.

Is BenevolentAI still publicly traded?

No. BenevolentAI listed on Euronext Amsterdam via SPAC merger in 2022 at roughly £1 billion valuation, but shares were delisted effective 13 March 2025 after a shareholder-approved merger into a private Luxembourg entity, following a share price collapse of over 90%.

Who is BenevolentAI's biggest competitor?

Isomorphic Labs is the most cited threat: a Google DeepMind spinout that closed a $2.1 billion Series B in May 2026, released its Drug Design Engine in February 2026, and holds partnerships with Novartis, Eli Lilly and Johnson & Johnson, all far outpacing BenevolentAI's resources.

AI companies and labs · United Kingdom

BenevolentAI

benevolent.com ↗

UK biotech using AI knowledge graphs to find new drug targets for pharma partners.

Losing its protection

Assessed 21 July 2026 · Evidence as of 21 July 2026

The structural protection is eroding.

On the recordSince 21 July 2026 · Checkable from before end of 2026 · Every call on the record Checkpoint: Isomorphic Labs' first human dosing of an AI-designed oncology drug

The call

BenevolentAI still holds real pharma contracts and clinical data, but a shrunk team, falling revenue, and a far richer AI rival leave its next moves uncertain.

BenevolentAI uses artificial intelligence to find new drug targets by analyzing medical data, but it has lost its speed advantage. Bigger AI labs like Isomorphic Labs (backed by Google) and its own customers like AstraZeneca and Merck are now building the same technology themselves or partnering with better-funded competitors, while BenevolentAI has cut staff from 363 people to 69 and lost 46% of revenue in one year. The company could change its situation if its existing drug candidates (especially BEN-8744) succeed in patient testing before 2027, or if a major partner like AstraZeneca or Merck commits serious new money, but without that, it risks being bought out cheaply or shut down as its cash reserves empty.

Why

AI pressure: Isomorphic Labs (Google DeepMind spinout). Isomorphic Labs' $2.1B war chest and DeepMind models aim at the same target ID work, with human dosing expected before end 2026. Could AI do the core job? Yes, likely.

Bigger players: AstraZeneca, Merck KGaA, Novartis. These same partners fund BenevolentAI's work while building internal AI teams and courting richer rivals like Isomorphic Labs. Could a giant copy it? Yes, easily.

What protects it. Existing AstraZeneca and Merck KGaA deals with milestone payments, plus its own BEN-8744 clinical data, keep some cash and credibility flowing.

What would change this call

Isomorphic Labs dosing first AI-designed oncology candidate in humans before end-2026. Would confirm frontier-lab drug design is outpacing BenevolentAI's knowledge-graph approach.
BenevolentAI announces new external funding round or names an acquirer within 12 months. Would show whether the company can extend runway past 2027 or is being absorbed.
AstraZeneca or Merck KGaA renews, expands, or ends its collaboration with BenevolentAI. Would show whether its remaining pharma partners still value its platform.

Key numbers

Staff cut from 363 to 69 (2025)
H1 2024 revenue fell 46% YoY to £2.8M (2024-H1)
Delisted from Euronext Amsterdam (2025-03-13)

Named risks

Cash runway explicitly extends only into 2027 with no disclosed new external funding. Severity: high
Headcount collapse from 363 to 69 (2023 to 2025) undermines execution capacity. Severity: high
Core knowledge-graph target-ID moat directly overlaps with better-funded frontier AI labs. Severity: high
Leadership structure unclear as of April 2026, conflicting reports on Mulvany vs Moeller CEO role. Severity: medium
Now private since March 2025, reducing financial transparency for external stakeholders. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Isomorphic Labs	losing to	$2.1B Series B May 2026 and Drug Design Engine Feb 2026 vs BenevolentAI's 69-person shrunk team
Insilico Medicine	losing to	First published Phase IIa data for a fully AI-discovered drug, June 2025
Recursion Pharmaceuticals/Exscientia	contesting	Merged 2024 to form combined AI drug discovery platform, scaling faster
Novartis (partner turned multi-sourcer)	losing to	Novartis renewed BenevolentAI deal 2024 while also partnering with Isomorphic Labs

Questions people ask

Is BenevolentAI profitable in 2026?: No. BenevolentAI has never reported profitability; H1 2024 revenue was £2.8 million, down 46% year-on-year, against an operating loss of £32.3 million (as of September 2024). The company delisted from Euronext Amsterdam in March 2025 and has disclosed no new external capital since.
Has BenevolentAI had major layoffs?: Yes, severe cuts. Headcount fell from 363 employees in January 2023 to just 69 by December 2025, roughly an 80% reduction, via multiple rounds including a 50% cut in May 2023 and a 30% cut plus US office closure in April 2024.
Who owns BenevolentAI now that it's delisted?: BenevolentAI became private on 13 March 2025 after merging into Osaka Holdings S.a r.l., which then renamed itself BenevolentAI. Founder Ken Mulvany, who became Executive Chairman in October 2024, reportedly held about 23% of shares as of April 2024.
Could AI replace BenevolentAI's core business?: BenevolentAI's core service, knowledge-graph-based drug target identification, sits directly in the path of better-funded frontier AI labs. Isomorphic Labs, a Google DeepMind spinout, raised a $2.1 billion Series B in May 2026 and shipped its Drug Design Engine in February 2026, targeting the same layer.
Is BenevolentAI still publicly traded?: No. BenevolentAI listed on Euronext Amsterdam via SPAC merger in 2022 at roughly £1 billion valuation, but shares were delisted effective 13 March 2025 after a shareholder-approved merger into a private Luxembourg entity, following a share price collapse of over 90%.
Who is BenevolentAI's biggest competitor?: Isomorphic Labs is the most cited threat: a Google DeepMind spinout that closed a $2.1 billion Series B in May 2026, released its Drug Design Engine in February 2026, and holds partnerships with Novartis, Eli Lilly and Johnson & Johnson, all far outpacing BenevolentAI's resources.

Timeline

2026-05Isomorphic Labs closes $2.1B Series B led by Thrive Capital
2026-02-10Isomorphic Labs releases Drug Design Engine (IsoDDE)
2025-06Insilico's rentosertib reports first Phase IIa data for fully AI-discovered drug
2025-03-13BenevolentAI shares delisted from Euronext Amsterdam
2025-03-12EGM approves merger into Osaka Holdings with over 95% shareholder support
2025-02-06Proposed delisting merger into Osaka Holdings S.A. announced
2024-12-11BenevolentAI announces major strategic overhaul, TechBio pivot, delisting exploration
2024-10-17Ken Mulvany named Executive Chairman
2024-04-2430% workforce cut (~75 staff) and US office closure
2024-03-25BEN-8744 reports positive Phase Ia safety and PK data

Revision history

21 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Safe Superintelligence Inc.Mistral AI Cohere